Precision Diabetes — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Precision Diabetes, Inc., founded in 2018 and based in Raleigh, North Carolina, is a commercial-stage diagnostics company focused on diabetes. Its core asset is the exclusive global rights to the GlycoMark test, a biomarker for detecting recent hyperglycemia and glycemic variability. The company is building a portfolio of novel diagnostic tests and algorithms, leveraging partnerships to expand its offerings, with the goal of personalizing diabetes prevention, management, and treatment.

DiabetesPrediabetesGestational Diabetes

Technology Platform

Leverages multi-omics data, proprietary algorithms, and artificial intelligence to develop and commercialize novel diabetes biomarkers and diagnostic tests for prevention, early detection, and personalized management.

Opportunities

The global shift towards precision medicine and value-based care creates a significant opportunity for specialized biomarkers that improve diabetes management outcomes.

Expanding clinical utility for GlycoMark into new indications (e.g., drug adherence, prediabetes) and launching a point-of-care version could drive substantial market penetration and revenue growth.

Risk Factors

Revenue is heavily concentrated on the GlycoMark test, creating single-product dependency.

Slow clinical adoption and challenges securing adequate insurance reimbursement for a novel biomarker pose major commercial risks.

The company also faces competition from larger diagnostic firms and alternative technologies.

Competitive Landscape

PDI competes in the diabetes diagnostics market against giants like Abbott, Roche, and Danaher, which dominate glucose and HbA1c testing. Its niche is competing on specificity with other specialized biomarkers (e.g., fructosamine) and emerging continuous glucose monitoring (CGM) data analytics. Its differentiation lies in GlycoMark's unique mechanism and its strategy of building an integrated diagnostic portfolio.

More companies in Diagnostics & Precision Medicine →More companies in United States →